, Tracking Stock Market Picks
Enter Symbol:
Medifast Inc (MED) [hlAlert]

up 11.33 %

Medifast Inc (MED) rated Outperform with price target $32 by Wedbush

Posted on: Wednesday,  Dec 1, 2010  9:25 AM ET by Wedbush

Wedbush rated Outperform Medifast Inc (NYSE: MED) on 12/01/2010, when the stock price was $25.05. Since
then, Medifast Inc has gained 11.34% as of 01/11/2016's recent price of $27.89.
If you would have followed this Wedbush 's recommendation on MED, you would have gained 11.33% of your investment in 1867 days.

Medifast, Inc. (Medifast) is engaged in the production, distribution, and sale of weight management and disease management products and other consumable health and diet products. The Company?s product lines include weight and disease management, meal replacement, and vitamins primarily manufactured in its modern, the United States Food and Drug Administration (FDA) approved facility in Owings Mills, Maryland. The Company?s operations are primarily conducted through five of its wholly owned subsidiaries, Jason Pharmaceuticals, Inc. (Jason), Take Shape for Life, Inc. (TSF), Jason Enterprises, Inc., Jason Properties, LLC and Seven Crondall, LLC. The Company offers a variety of weight and disease management products under the Medifast brand and for select private label customers. It's distribution channels include Medifast Direct, Take Shape for Life, Medifast Weight Control Centers and Medifast Physicians.

Wedbush is Headquartered in Los Angeles, California with over 90 offices and more than 125 correspondent offices, our commitment to providing relentless, customized service is the foundation of our consistent growth. We deliver superior investment ideas and products through exceptional customer care, financial security, continuity and advanced technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/1/2010 9:25 AM Buy
25.05 32.00
as of 12/31/2010
1 Week down  -21.08 %
1 Month down  -2.71 %
3 Months   
1 YTD down  -2.71 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy